Kur Józef, Holec-Gasior Lucyna, Hiszczyńska-Sawicka Elzbieta
Gdańsk University of Technology, Chemical Faculty, Department of Microbiology, Narutowicza 11/12, 80-952 Gdańsk, Poland.
Expert Rev Vaccines. 2009 Jun;8(6):791-808. doi: 10.1586/erv.09.27.
Toxoplasmosis, caused by an intracellular protozoan parasite, Toxoplasma gondii, is widespread throughout the world. The disease is of major medical and veterinary importance, being a cause of congenital disease and abortion in humans and domestic animals. In addition, recently it has gained importance owing to toxoplasma encephalitis in AIDS patients. In the last few years, there has been considerable progress towards the development of a vaccine for toxoplasmosis, and a vaccine based on the live-attenuated S48 strain was developed for veterinary uses. However, this vaccine is expensive, causes side effects and has a short shelf life. Furthermore, this vaccine may revert to a pathogenic strain and, therefore, is not suitable for human use. Various experimental studies have shown that it may be possible to develop a vaccine against human toxoplasmosis. Recent progress in knowledge of the protective immune response generated by T. gondii and the current status of development of a vaccine for toxoplasmosis are highlighted.
弓形虫病由细胞内原生动物寄生虫刚地弓形虫引起，在全球广泛传播。该疾病在医学和兽医学上具有重要意义，是人类和家畜先天性疾病及流产的病因。此外，由于艾滋病患者的弓形虫性脑炎，其重要性近来有所增加。在过去几年中，弓形虫病疫苗的研发取得了相当大的进展，一种基于减毒活S48株的疫苗已被开发用于兽医领域。然而，这种疫苗价格昂贵，会产生副作用且保质期短。此外，这种疫苗可能会回复为致病菌株，因此不适合人类使用。各种实验研究表明，有可能开发出一种针对人类弓形虫病的疫苗。本文重点介绍了刚地弓形虫产生的保护性免疫反应的知识最新进展以及弓形虫病疫苗的当前研发状况。
